Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
A practical review of the neuropathology and neuroimaging of multiple sclerosis.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Treatment of multiple sclerosis with anti-CD20 antibodies.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Confounding in association studies: month of birth and multiple sclerosis.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.

Pages